Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells

被引:40
作者
Forsea, AM
Müller, C
Riebeling, C
Orfanos, CE
Geilen, CC
机构
[1] Charite Univ Med Ctr Berlin, Dept Dermatol, D-14195 Berlin, Germany
[2] Carol Davila Univ Med & Pharm, Colentina Hosp, Clin Dermatol 1, Bucharest, Romania
[3] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel
关键词
melanoma; bisphosphonates; apoptosis; cell cycle;
D O I
10.1038/sj.bjc.6602052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cutaneous melanoma is one of the highly malignant human tumours, due to its tendency to generate early metastases and its resistance to classical chemotherapy. We recently demonstrated that pamidronate, a nitrogen-containing bisphosphonate, has an antiproliferative and proapoptotic effect on different melanoma cell lines. In the present study, we compared the in vitro effects of three different bisphosphonates on human melanoma cell lines and we demonstrated that the two nitrogen-containing bisphosphonates pamidronate and zoledronate inhibited the proliferation of melanoma cells and induced apoptosis in a dose- and time-dependent manner. Moreover, cell cycle progression was altered, the two compounds causing accumulation of the cells in the S phase of the cycle. In contrast, the nonaminobisphosphonate clodronate had no effect on melanoma cells. These findings suggest a direct antitumoural effect of bisphosphonates on melanoma cells in vitro and further support the hypothesis of different intracellular mechanisms of action for nitrogen-containing and nonaminobisphosphonates. Our data indicate that nitrogen-containing bisphosphonates may be a useful novel therapeutic class for treatment and/or prevention of melanoma metastases.
引用
收藏
页码:803 / 810
页数:8
相关论文
共 53 条
  • [1] In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
    Aparicio, A
    Gardner, A
    Tu, Y
    Savage, A
    Berenson, J
    Lichtenstein, A
    [J]. LEUKEMIA, 1998, 12 (02) : 220 - 229
  • [2] Rho signals to cell growth and apoptosis
    Aznar, S
    Lacal, JC
    [J]. CANCER LETTERS, 2001, 165 (01) : 1 - 10
  • [3] Ras and Rho GTPases: A family reunion
    Bar-Sagi, D
    Hall, A
    [J]. CELL, 2000, 103 (02) : 227 - 238
  • [4] Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates:: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
    Benford, HL
    Frith, JC
    Auriola, S
    Mönkkönen, J
    Rogers, MJ
    [J]. MOLECULAR PHARMACOLOGY, 1999, 56 (01) : 131 - 140
  • [5] Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
    Benford, HL
    McGowan, NWA
    Helfrich, MH
    Nuttall, ME
    Rogers, MJ
    [J]. BONE, 2001, 28 (05) : 465 - 473
  • [6] Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function
    Berenson, JR
    Rosen, L
    Vescio, R
    Lau, HS
    Woo, M
    Sioufi, A
    Kowalski, O
    Knight, RD
    Seaman, JJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (04) : 285 - 290
  • [7] Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
    Bergstrom, JD
    Bostedor, RG
    Masarachia, PJ
    Reszka, AA
    Rodan, G
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 373 (01) : 231 - 241
  • [8] Boissier S, 2000, CANCER RES, V60, P2949
  • [9] Genomic analysis of metastasis reveals an essential role for RhoC
    Clark, EA
    Golub, TR
    Lander, ES
    Hynes, RO
    [J]. NATURE, 2000, 406 (6795) : 532 - 535
  • [10] The antitumor potential of bisphosphonates
    Clézardin, P
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 33 - 42